Rationale and Design of the REPRESS Trial: InclisiRan for Early Passivation of VulneRable AthEroSclerotic PlaqueS in Patients with Acute Coronary Syndromes
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Inclisiran (Primary) ; Atorvastatin; Rosuvastatin
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms REPRESS
- 03 Feb 2025 New trial record